Generic Name and Formulations:
Glyburide 1.25mg, 2.5mg, 5mg; scored tabs.
Indications for DIABETA:
Adjunct to diet and exercise in type 2 diabetes mellitus.
Initially 2.5–5mg daily with breakfast or first main meal. Elderly or debilitated: initially 1.25mg daily. Increase by 2.5mg at weekly intervals if needed per blood glucose. Maintenance: 1.25–20mg daily in single or divided doses (consider divided doses above 10mg daily); max 20mg daily.
Type 1 diabetes or diabetic ketoacidosis with or without coma. Concomitant bosentan.
Oral hypoglycemic agents may increase risk of cardiovascular mortality. Renal or hepatic impairment. Adrenal or pituitary insufficiency. Stress. Secondary failure may occur with extended therapy. Risk of hemolytic anemia in G6PD deficiency; consider non-sulfonylurea alternative. Monitor urine, fasting blood glucose, and HbA1c levels periodically. Discontinue if jaundice or hepatitis occurs. Sulfonamide allergy. Malnourished. Elderly. Debilitated. Pregnancy (Cat.C): consider using insulin instead. Nursing mothers: not recommended.
Sulfonylurea (2nd generation).
See Contraindications. May be potentiated by NSAIDs, ACEIs, disopyramide, fluoxetine, clarithromycin, coumarin, alcohol, highly protein bound drugs, salicylates, sulfonamides, chloramphenicol, probenecid, MAOIs, β-blockers, oral miconazole (possibly), fluroquinolones. Antagonized by diuretics, steroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, niacin, sympathomimetics, calcium channel blockers, isoniazid. Monitor closely for hypoglycemia with concomitant drugs that affect glucose metabolism and upon withdrawal. May increase cyclosporine levels; monitor and adjust cyclosporine dose. Caution with CYP2C9 inhibitors or inducers (eg, rifampin). May be antagonized by topiramate, colesevelam; administer glyburide ≥4hrs prior to colesevelam. Disulfiram-like reaction with alcohol (rare). Monitor for 2 weeks if transferring from chlorpropamide.
Hypoglycemia, nausea, epigastric fullness, heartburn, allergic skin reactions, photosensitivity, blood dyscrasias; rare: cholestatic jaundice, hepatitis.
Tabs 1.25mg—50; 2.5mg—100; 5mg—100, 1000
Neurology Advisor Articles
- Erenumab Superior to Placebo for Reducing Migraine Disability, Improving HRQoL
- Congress Passes Bill to Fight Opioid Crisis
- Managing Status Epilepticus in Palliative Care: Accounting for Patient and Family Experience
- Physical Activity Decreases Vascular Comorbidities in Multiple Sclerosis
- Review of Factors Impacting Sport-Related Concussion Headaches
- Anodal tDCS Offers Possible Benefit for Improving Item Recall in Post-Stroke Aphasia
- Hospitalization Tied to Brain Abnormalities in Older Adults
- Spending Often Persists in High-Cost Medicare-Medicaid Eligible
- Skills-Based Intervention Did Not Cut Systolic BP After Stroke, TIA
- High Frequency of Headaches Following Dialysis Associated With BUN and Blood Pressure